The Molecular Pathogenesis of Osteosarcoma: A Review
Osteosarcoma is the most common primary malignancy of bone. It arises in bone during periods of rapid growth and primarily affects adolescents and young adults. The 5-year survival rate for osteosarcoma is 60%–70%, with no significant improvements in prognosis since the advent of multiagent chemothe...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2011-01-01
|
Series: | Sarcoma |
Online Access: | http://dx.doi.org/10.1155/2011/959248 |
id |
doaj-c410c31dddd04a91b28d36d0f11464a4 |
---|---|
record_format |
Article |
spelling |
doaj-c410c31dddd04a91b28d36d0f11464a42020-11-24T21:32:02ZengHindawi LimitedSarcoma1357-714X1369-16432011-01-01201110.1155/2011/959248959248The Molecular Pathogenesis of Osteosarcoma: A ReviewMatthew L. Broadhead0Jonathan C. M. Clark1Damian E. Myers2Crispin R. Dass3Peter F. M. Choong4Department of Orthopaedics, Department of Surgery, University of Melbourne, St. Vincent's Hospital, SVHM, L3, Daly Wing, 35 Victoria Parade, Fitzroy VIC 3065, AustraliaDepartment of Orthopaedics, Department of Surgery, University of Melbourne, St. Vincent's Hospital, SVHM, L3, Daly Wing, 35 Victoria Parade, Fitzroy VIC 3065, AustraliaDepartment of Orthopaedics, Department of Surgery, University of Melbourne, St. Vincent's Hospital, SVHM, L3, Daly Wing, 35 Victoria Parade, Fitzroy VIC 3065, AustraliaSchool of Biomedical and Health Sciences, Victoria University, St. Albans, VIC 3021, AustraliaDepartment of Orthopaedics, Department of Surgery, University of Melbourne, St. Vincent's Hospital, SVHM, L3, Daly Wing, 35 Victoria Parade, Fitzroy VIC 3065, AustraliaOsteosarcoma is the most common primary malignancy of bone. It arises in bone during periods of rapid growth and primarily affects adolescents and young adults. The 5-year survival rate for osteosarcoma is 60%–70%, with no significant improvements in prognosis since the advent of multiagent chemotherapy. Diagnosis, staging, and surgical management of osteosarcoma remain focused on our anatomical understanding of the disease. As our knowledge of the molecular pathogenesis of osteosarcoma expands, potential therapeutic targets are being identified. A comprehensive understanding of these mechanisms is essential if we are to improve the prognosis of patients with osteosarcoma through tumour-targeted therapies. This paper will outline the pathogenic mechanisms of osteosarcoma oncogenesis and progression and will discuss some of the more frontline translational studies performed to date in search of novel, safer, and more targeted drugs for disease management.http://dx.doi.org/10.1155/2011/959248 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Matthew L. Broadhead Jonathan C. M. Clark Damian E. Myers Crispin R. Dass Peter F. M. Choong |
spellingShingle |
Matthew L. Broadhead Jonathan C. M. Clark Damian E. Myers Crispin R. Dass Peter F. M. Choong The Molecular Pathogenesis of Osteosarcoma: A Review Sarcoma |
author_facet |
Matthew L. Broadhead Jonathan C. M. Clark Damian E. Myers Crispin R. Dass Peter F. M. Choong |
author_sort |
Matthew L. Broadhead |
title |
The Molecular Pathogenesis of Osteosarcoma: A Review |
title_short |
The Molecular Pathogenesis of Osteosarcoma: A Review |
title_full |
The Molecular Pathogenesis of Osteosarcoma: A Review |
title_fullStr |
The Molecular Pathogenesis of Osteosarcoma: A Review |
title_full_unstemmed |
The Molecular Pathogenesis of Osteosarcoma: A Review |
title_sort |
molecular pathogenesis of osteosarcoma: a review |
publisher |
Hindawi Limited |
series |
Sarcoma |
issn |
1357-714X 1369-1643 |
publishDate |
2011-01-01 |
description |
Osteosarcoma is the most common primary malignancy of bone. It arises in bone during periods of rapid growth and primarily affects adolescents and young adults. The 5-year survival rate for osteosarcoma is 60%–70%, with no significant improvements in prognosis since the advent of multiagent chemotherapy. Diagnosis, staging, and surgical management of osteosarcoma remain focused on our anatomical understanding of the disease. As our knowledge of the molecular pathogenesis of osteosarcoma expands, potential therapeutic targets are being identified. A comprehensive understanding of these mechanisms is essential if we are to improve the prognosis of patients with osteosarcoma through tumour-targeted therapies. This paper will outline the pathogenic mechanisms of osteosarcoma oncogenesis and progression and will discuss some of the more frontline translational studies performed to date in search of novel, safer, and more targeted drugs for disease management. |
url |
http://dx.doi.org/10.1155/2011/959248 |
work_keys_str_mv |
AT matthewlbroadhead themolecularpathogenesisofosteosarcomaareview AT jonathancmclark themolecularpathogenesisofosteosarcomaareview AT damianemyers themolecularpathogenesisofosteosarcomaareview AT crispinrdass themolecularpathogenesisofosteosarcomaareview AT peterfmchoong themolecularpathogenesisofosteosarcomaareview AT matthewlbroadhead molecularpathogenesisofosteosarcomaareview AT jonathancmclark molecularpathogenesisofosteosarcomaareview AT damianemyers molecularpathogenesisofosteosarcomaareview AT crispinrdass molecularpathogenesisofosteosarcomaareview AT peterfmchoong molecularpathogenesisofosteosarcomaareview |
_version_ |
1725958850797895680 |